// App-Quantinova.ai

P4-22-16 : First-line ribociclib + letrozole in patients with HR+, HER2 advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial

Researchers

Presenter

  • HA Burris

Principal Investigators

  • A Chan

  • M Campone

  • KL Blackwell

  • EP Winer

  • W Janni

  • S Verma

  • O Burdaeva

  • E Alba

  • AM Favret

  • S Mondal

  • M Miller

  • C Germa

  • S Hirawat

  • YS Yap

Medical Centers

  • Universitatsklinikum Ulm, Ulm, Germany

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Dana-Farber Cancer Institute, Boston, MA

  • Duke University Medical Center, Durham, NC

  • IBIMA-Hospital Regional Universitario y Virgen de la Victoria, Malaga, Spain

  • Institut de Cancerologie de lOuest - Rene Gauducheau, Centre de Recherche en Cancerologie, Saint Herblain-Nantes, France

  • Virginia Cancer Specialists, Arlington, VA

  • National Cancer Centre Singapore, Singapore, Singapore

  • Breast Cancer Research Centre - WA & Curtin University, Perth, Australia

Locations

  • Canada

  • Singapore

  • Germany

  • Spain

  • Australia

  • United States

  • France

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Secondary liver cancer

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Aspartate aminotransferase

  • Cyclin-dependent kinase 4

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Ribociclib

  • Letrozole

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • NCT01958021

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved